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Abstract
NAD+ metabolism is integrally connected with the mechanisms of action of radiation therapy and 
is altered in many radiation-resistant tumors. This makes NAD+ metabolism an ideal target for 
therapies that increase radiation sensitivity and improve patient outcomes. This review provides an 
overview of NAD+ metabolism in the context of the cellular response to ionizing radiation, as well 
as current therapies that target NAD+ metabolism to enhance radiation therapy responses. 
Additionally, we summarize state-of-the-art methods for measuring, modeling, and manipulating 
NAD+ metabolism, which are being used to identify novel targets in the NAD+ metabolic network 
for therapeutic interventions in combination with radiation therapy.
Introduction
Nicotinamide adenine dinucleotide (NAD+) is an omnipresent molecule which acts as both 
an electron-carrying cofactor for oxidation-reduction reactions, as well as a substrate for 
many metabolic and signaling processes [1]. NAD+ metabolism has been implicated in 
several important biological processes, including energy production, cell signaling, and 
redox homeostasis. This metabolism is altered in natural physiological processes such as 
aging, metabolic diseases (e.g., pellagra and type 2 diabetes), and many forms of cancer [2]. 
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Because of its essential role in the pathophysiology of many prevalent diseases, NAD+ 
metabolism remains an exciting yet challenging target for selective therapies.
Many processes in the NAD+ metabolic network are disrupted in cancer, including the 
production of NAD+ intermediates and consumption of NAD+ by signaling processes 
necessary for tumor cell survival [3, 4]. Ionizing radiation therapy used in cancer treatment 
further disrupts NAD+ metabolism and the processes regulating NAD+ production and 
consumption. Radiation-resistant tumors are capable of maintaining adequate NAD+ 
production while overcoming the damaging effects of radiation on DNA damage and 
reactive oxygen species (ROS) production [5]. Thus, it is expected that selectively targeting 
NAD+ metabolism will sensitize tumor cells to ionizing radiation, and that these targeting 
agents can be combined with radiation therapy to improve cancer patient outcomes. Current 
NAD+-targeting chemotherapies have shown very promising results as radiation sensitizers, 
and novel methods of measuring and modeling NAD+ metabolism will both improve our 
biological understanding and provide new insights into targeting NAD+ metabolism to 
enhance radiation therapy responses.
NAD+ Metabolism and its Role in Radiation Response
NAD+ synthesis
Nicotinic acid mononucleotide (NAMN), a precursor of NAD+, can be formed from either 
quinolinic acid (originating from tryptophan) in the de novo NAD+ synthesis pathway, or 
from nicotinic acid in the Preiss-Handler pathway (Figure 1A) [6, 7]. NAMN is then 
converted to nicotinate adenine dinucleotide (NAAD) by nicotinamide mononucleotide 
adenylyl transferase (NMNAT), and then converted into NAD+ by NAD+ synthase. By 
utilizing salvage pathways, NAD+ can also be produced using available precursors such as 
nicotinamide (NAM) and nicotinamide riboside (NR). The rate-limiting enzyme in these 
salvage pathways is nicotinamide phosphoribosyltransferanse (NAMPT), which converts 
nicotinamide to nicotinamide mononucleotide (NMN) [8].
NAMPT inhibitors are effective inhibitors of NAD+ synthesis and are being used in clinical 
trials for cancer treatment due to the higher demand of tumor cells for NAD+ [9]. Since 
NAD+ salvage pathways may be overutilized compared to the de novo and Preiss-Handler 
pathways in some cancers, NAMPT is a very promising target for cancer therapies [10]. 
Alternatively, because of its utilization in both de novo and salvage pathways, NMNAT may 
be an effective target for suppression of NAD+ synthesis as well. Complete loss of function 
of NMNAT in Drosophila causes severe Wallerian degeneration, whereas NMNAT 
overexpression is neuroprotective and associated with decreased levels of reactive oxygen 
species (ROS); however, it is unclear whether these effects are due to changes in NAD+ 
levels through increased biosynthesis, increases in the NADH/NAD+ ratio, or both [11, 12].
Redox cycling of NAD+
Glucose oxidation supplies a significant amount of energy for the transfer of electrons from 
NAD+ to NADH (Figure 1B). Glycolysis via glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), oxidative carboxylation of pyruvate via the pyruvate dehydrogenase complex 
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(PDC), and the citric acid cycle via isocitrate dehydrogenase isoform 3 (IDH3), the α-
ketoglutarate dehydrogenase complex (αKGDH), and malate dehydrogenase (MDH) 
produce a combined 10 NADH per glucose molecule. In addition, beta oxidation of fatty 
acid molecules provides energy for NAD+ reduction via 3-hydroxyacyl-CoA dehydrogenase. 
Other enzymes that are involved in reduction of NAD+ to NADH include glutamate 
dehydrogenase (GLUD), malic enzyme (ME) and methylenetetrahydrofolate dehydrogenase 
2-like protein (MTHFD2L). Whereas some enzymes are specific to the NAD+ cofactor 
(including ME2), others can non-specifically reduce both NAD+ and NADP+ (including 
GLUD1/2) with varying catalytic efficiencies. Cytosolic and mitochondrial NADH can be 
exchanged via the malate-aspartate and glycerol-3-phosphate shuttles [6]. The reduced form 
of NADPH is the dominant intracellular form (NADP+/NADPH ~ 1:100) while the oxidized 
form of NAD+ is maintained at much higher levels than reduced NADH (NAD+/NADH ~ 3 
to >100, depending on subcellular compartment as well as free versus protein-bound states) 
[13, 14].
Role of NAD+ in radiation response
Oxidative stress caused by ionizing radiation causes release of the transcription factor, Nrf2, 
by Keap1 in the cytoplasm, allowing Nrf2 translocation to the nucleus [15]. Nrf2 binds to 
the antioxidant response element (ARE), a transcription factor binding site found in the 
promoter region of many genes involved in antioxidation and detoxification, and increases 
expression of these genes [16]. The canonical Nrf2-induced gene product, the cytosolic 
flavoenzyme NAD(P)H:quinone oxidoreductase 1 (NQO1), uses NADH (as well as 
NADPH) to reduce and detoxify quinone compounds that cause ROS generation and further 
oxidative stress [17]. Nrf2 also increases the concentration of reduced NADPH by increasing 
expression of NADP+ reducing enzymes, including G6PD, PGD, and ME1 [18, 19]. 
Increased levels of NADPH exert antioxidant effects by providing reducing equivalents for 
reduction of oxidized glutathione by glutathione reductase, as well as recycling of 
peroxiredoxins through the thioredoxin/thioredoxin reductase systems in various subcellular 
compartments. NAD+ can contribute to the NADPH pool via phosphorylation by NAD+ 
kinase into NADP+. The promoter of IDH3A contains an ARE, and increased IDH3A 
expression may promote NADH production in response to oxidative stress [20].
Ionizing radiation causes significant DNA damage, including the formation of single-
stranded DNA breaks (SSBs). The DNA single-strand break recognition domain of 
poly(ADP-ribose) polymerase 1 (PARP1) recognizes these SSBs within seconds of damage, 
causing the formation of a PARP1 homodimer at the site of damage [21, 22]. By catalyzing 
the breakdown of NAD+ into ADP-ribose and nicotinamide, PARP1 promotes the poly 
ADP-ribosylation of other target proteins as needed for DNA repair, as well as itself, which 
causes conformation changes in the PARP enzyme and inactivates it to allow for repair. 
PARP-mediated ADP ribosylation causes recruitment of XRCC1, DNA polymerase β, and 
DNA ligase III to repair the SSBs. DNA damage in the form of double-stranded DNA breaks 
(DSBs) can cause activation of sirtuins, which are involved in a number of cellular 
processes, including the repair of DSBs [23]. Sirtuins catalyze the deacetylation of lysine 
residues on proteins; the acetyl groups are transferred to NAD+, resulting in the breakdown 
of NAD+ into nicotinamide and O-acetyl-ADP-ribose [24].
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The activation of both PARP1 and sirtuins by ionizing radiation causes a significant 
depletion of cellular stores of NAD+ [25]. These stores can be replenished by increasing flux 
through the NAD+ salvage pathways. However, consumption of ATP by NMNAT, one of the 
critical enzymes in NAD+ salvage, causes significant depletion of ATP stores. PARP’s role 
in deciding cell fate depends on the type, duration, and strength of the stress stimuli, as well 
as the metabolic and proliferative status of the cell [26]. In the presence of a low level of 
DNA damage, PARP activation may promote cell survival; on the other hand, the presence 
of widespread DNA damage causes PARP hyperactivation, severe NAD+/ATP depletion, and 
programmed necrosis [27].
Sensors and Modulators of NAD+ and NADH
Measurement of NAD+ and NADH in cells and tissue lysates
NAD+ and NADH have been measured in cell and tissue lysates using enzymatic cycling 
assays coupled to absorbance or fluorescence detection methods, capillary electrophoresis 
[28], high-performance liquid chromatography (HPLC) [29], and high-performance liquid 
chromatography coupled to mass spectrometry (LC-MS) [30] (Table 1). As NAD+ and 
related metabolites are reactive and vary in cellular concentration from ~1 μM to ~1 mM, 
these methods face many technical challenges [30]. Enzymatic cycling assays are limited in 
sensitivity, LC-based methods can be compromised in complex samples, and even though 
mass spectrometry accurately measures small molecules in complex samples, the conditions 
and separation of metabolites need to be optimized [30]. Additionally, for all these methods, 
proper extraction and preservation of the metabolites to avoid degradation and 
interconversion is essential for accuracy of the analysis [31].
Cellular measurement
In this section we outline the current approaches for measuring intracellular NAD+, NADH, 
or their ratios. These were recently reviewed in more detail [32–34].
Autofluorescence detection.—Cellular NADH can be measured directly based on its 
ability to absorb light at 340 nm and emit fluorescence at 460 nm. This weak endogenous 
fluorescence has been studied by single-photon or multiphoton excitation, but these studies 
have been limited by sensitivity of these methods and cell injury caused by ultraviolet 
irradiation [35]. The spectral properties of NADH are identical to those of NADPH, and thus 
the detectable fluorescence signal reflects both NADH and NADPH in cells. The 
contributions of each to the total signal can be separated using fluorescence lifetime imaging 
microscopy (FLIM) [34, 36]. Also, it has been very difficult to separate cytosolic signals 
from the intense mitochondrial signals because intrinsic NADH and NADPH fluorescence 
signals mostly originate from the mitochondria [32].
Genetically encoded NAD+ and NADH sensors.—Compared to endogenous 
NAD(P)H fluorescence, genetically encoded NAD+ and NADH sensors provide alternatives 
with considerable advantages. The genetically encoded sensors produce higher fluorescence 
compared to NAD(P)H autofluorescence, improving the sensitivity of assays. Additionally, 
they also enable detection of NAD+ and NADH with high selectivity and without significant 
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interference from NADPH [32–34]. Currently there are four genetically encoded NADH 
sensors: Frex [37], Peredox [38], rexYFP [39] and SoNar [40]. These sensors are based on 
the different members of the Rex-family proteins that are fused with circularly permuted 
fluorescent proteins (cpFPS). The Rex proteins have much higher affinity to NADH than 
NAD+, and in bacteria function as gene repressors that sense the NAD+/NADH redox state. 
Frex, rexYFP and SoNar detection is based on the yellow fluorescent protein (YFP), which 
makes them sensitive to pH changes, whereas Peredox contains a pH-insensitive circular 
permutated T-sapphire fluorescent protein to eliminate the pH sensitivity. Frex measures 
NADH, whereas Peredox and rexYFP sense shifts in NAD+/NADH ratio. SoNar is the only 
sensor that responds to both NADH and NAD+, but as its signal remains unaffected by the 
total NAD(H) pool, it cannot be used to quantify the NAD+ or NADH separately, except for 
in vitro studies where only one form is present [35]. SoNar has an intense fluorescence with 
a large dynamic range and rapid kinetics compared to other probes, making it most suitable 
for in vivo studies [35].
In addition, one genetically encoded sensor for detection of free NAD+ has been developed 
[41]. This sensor is based on the specific NAD+-binding domain modeled from bacterial 
DNA ligase that is fused with circularly permuted fluorescent protein cpVenus. This sensor 
is only minimally affected by pH in the range of 6.5–8.0; however, the temperature has a 
slight effect on the fluorescence intensity [41]. These genetically encoded indicators for 
NAD+ and NADH can be transiently or stably expressed in various types of cells and 
targeted to different subcellular compartments. Various techniques, such as imaging, flow 
cytometry, or fluorescence reading (e.g., microplate readers) can be used to monitor changes 
in the NAD+ and NADH redox state using these sensors [32–34].
In vivo imaging
31P and 1H nuclear magnetic resonance (NMR) methods have been developed for the non-
invasive measurement of NAD+ concentrations and NAD+/NADH ratio in animal and 
human brains in vivo [42, 43]. The 31P-NMR signal of the total NAD(H) pool has been 
observed since the early days of in vivo 31P-NMR, but now the availability of high/ultra high 
magnetic field strengths and spectral fitting routines can separate the NAD+ and NADH 
contributions to the observed NMR signals. These methods were used to study the NAD+/
NADH ratios in brains of healthy, aging, and Parkinson’s disease populations [42, 43]. As 
mentioned above, SoNar was also shown to be suitable for in vivo studies and was used for 
fluorescent imaging of NAD+/NADH ratio in tumor xenografts in mice [35].
Modulators of NAD+/NADH ratio
To complement the studies measuring NAD+ and NADH, tools for manipulating these 
species are needed for mechanistic investigations of NAD+ or NADH-dependent 
metabolism. LbNOX is a recently developed genetically encoded tool based on the bacterial 
NADH oxidase (NOX) from Lactobacillus brevis [44]. NOX catalyzes a four-electron 
reduction of oxygen to water using reducing equivalents of NADH, and its natural function 
is protection of redox balance and defense against oxygen toxicity. In HeLa cells, both 
LbNOX and its mitochondria-targeted version mitoLbNOX decreased NADH levels in the 
cytosol as measured by SoNar. However, only mitoLbNOX impacted total cellular NADH 
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measured by HPLC [44]. A limitation of these systems is the lack of substrate control: when 
expressed in cells these proteins oxidize NADH, and there is no possibility to control the 
level and duration of reaction by substrate. Consumption of O2 could lead to onset on 
hypoxia and broad perturbation of cellular signaling and metabolism. It is also not possible 
to reverse the reaction towards reduction of NAD+ with the LbNOX system as the reaction 
product is H2O.
NAD-Targeting Therapies to Enhance Radiation Response
Ratio of NQO1 vs CAT expression
High-level expression of NAD(P)H:quinone oxidoreductase 1 (NQO1) has been linked to 
the progression of different human cancers, including lung, breast, liver, colon, pancreatic, 
thyroid, adrenal, ovary, colon, bladder, head and neck, and colorectal [45–49]. In non-small 
cell lung cancer (NSCLC) patient tumor samples, significantly elevated mRNA expression 
of NQO1 was observed compared to lower catalase (CAT) expression [17, 50, 51]. Western 
analyses showed lowered CAT levels and higher NQO1 levels in NSCLC compared to 
normal lung tissue [50]. Over-expression of NQO1 was observed in advanced NSCLC and 
treatment-resistant NSCLC patient tumor samples [50]. Immunohistochemical staining and 
Western blot assays also showed elevated expression of NQO1 and lower catalase expression 
in head and neck cancer, breast cancer, and pancreatic ductal adenocarcinoma [45, 48, 49]. 
The inverse expression pattern of NQO1 and catalase presents an ideal therapeutic target by 
selectively killing cancer cells with high NQO1 expression levels.
Enhanced antitumor efficacy of NQO1-bioactivatable drugs with ionization radiation
β-Lapachone (β-lap, ARQ761 in clinical form) is an NQO1-bioactivated naphthoquinone 
chemotherapeutic that generates an unstable hydroquinone which spontaneously reacts with 
two oxygen molecules in a two-step futile cycle to regenerate the original compound [51]. 
This futile redox cycling oxidizes ~60 moles of NAD(P)H to create ~120 moles of reactive 
oxygen species (ROS) in ~2 mins, leading to the generation of permeable hydrogen peroxide 
(H2O2) that diffuses into the nucleus and causes massive oxidative base and single-strand 
breaks (SSB) [45]. β-Lapachone has exhibited tumor-selective cytotoxic effects and caspase-
independent programmed necrosis in several NQO1+ cancer cells and solid tumors, 
including pancreatic ductal adenocarcinoma (MiaPaCa2), breast (TNBC: MDA-MB-231 
NQO1+/−, Luminal: MCF-7), colon (HCT116), non-small cell lung (H596 and A549), 
prostate (LNCaP NQO1+ vs NQO1-), and head and neck cancers [45, 49–54]. PDA and 
NSCLC cells showed severe lethality and loss of NAD+/NADH after 2 hours of β-lapachone 
treatment (≥ 4 μM), resulting in PARP hyper-activation, DNA damage, and alterations in 
metabolic homeostasis [50–52]. Additionally, NQO1 knockout and stable NQO1 shRNA-
knockdown PDA and NSCLC cells were highly resistant to β-lapachone toxicity [50, 51].
Sub-lethal doses of β-lapachone exploit NQO1 to release massive levels of reactive oxygen 
species (ROS), resulting in synergism with ionizing radiation and increased programmed 
necrosis [55, 56]. HNC cells and tumors were shown to be sensitive to non-toxic doses of β-
lapachone combined with IR. This combination significantly improved NQO1-dependent 
tumor cell lethality, increased ROS, DNA damage, γH2AX foci formation, NAD+ and ATP 
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consumption, and μ-calpain–induced programmed cell death in HNC cells (FaDu, SqCC/Y1 
and Detroit 562: NQO1+, UM-SCC-10A: NQO1-), two xenografts murine HNC models, as 
well as prostate cancer cells [49, 57] (Figure 2). Mice bearing 30 mm3 SqCC/Y1 HNC 
xenografts (high levels of NQO1 expression) were treated with 2 Gy IR every other day for 
five treatments (10 Gy total dose) [49]. β-Lapachone HPβ-CD 10 mg/kg was intravenously 
administered by tail vein injection immediately followed by 2 Gy IR treatment [49] This 
combination therapy resulted in significant DNA base damage (both single-stranded and 
double-stranded breaks) in HNC cells [49, 55, 57].
PARP inhibitors for increasing radiation sensitivity
The rapid accumulation of DNA lesions from β-lapachone treatment leads to hyperactivation 
of PARP1 by overwhelming the cell’s DNA repair capacity, followed by rapid protein 
PARylation including PAR-PARP1, severe NAD+/ATP depletion, massive DNA lesions, and 
repair inhibition [58]. Combining PARP inhibitors with the highly tumor-specific DNA-
damaging agent ß-lapachone results in synergy at nontoxic doses of both drugs in NQO1+ 
over-expressing non-small cell lung (NSCLC), pancreatic ductal adenocarcinoma (PDA) and 
breast cancers, including triple-negative breast cancers (TNBC) [50]. PARP inhibitors 
prevent auto-poly-ADP-ribosylation, preventing release from DNA and access of SSBs to 
DNA repair proteins. Unrepaired SSBs can lead to DSBs (collision of unrepaired SSB with 
replication fork in S-phase), enhancing the effect of radiation [22]. When using higher β-
lapachone doses, including a PARP inhibitor prevents NAD+ loss and replenishes NAD(P)H 
levels for increased futile cycling and ROS generation.
NAMPT inhibitors for increasing radiation sensitivity
Increased expression of NAMPT was reported in colorectal, non-small cell lung (NSCL), 
prostate and pancreatic cancer [59–63]. NAMPT serves as an important source of reducing 
equivalents for redox balance within the cancer cell [60]. NAMPT inhibitors such as FK866 
have been shown to decrease NAD+ levels and inhibit tumor growth [64]. Pre-treatment of 
NQO1+ cancer cells with FK866 reduced overall NAD+/NADH pool sizes prior to β-
lapachone treatment, which led to an accelerated decrease in NAD+/NADH levels and shifts 
in lethality of β-lapachone to smaller doses of the drug [65]. Overall, treatment with FK866 
attenuates the effects of β-lapachone without causing excess PAR formation due to lower 
NAD+ levels, and makes the NAMPT inhibitor tumor-selective. NAMPT knockdown 
sensitizes prostate and head and neck cancer cell lines to ROS induction from ionizing 
radiation [60, 66–68].
Modeling Approaches for Target Discovery in NAD+ Metabolism
Genome-scale metabolic modeling for target discovery
From genome-scale reconstructions of human metabolism, it is estimated that NAD+ and 
NADH are involved in over 600 different metabolic reactions, acting as both a redox 
cofactor as well as a metabolic substrate [69]. Whereas experimentally studying each of 
these reactions and their interconnections in the context of NAD+ metabolism would be 
infeasible, computational methods have been developed to efficiently study the human 
metabolic network on a genome scale. Flux balance analysis (FBA), one of the most 
Lewis et al. Page 7
Semin Radiat Oncol. Author manuscript; available in PMC 2020 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
common of these methods, is a metabolic modeling methodology that allows for the 
prediction of steady-state reaction fluxes throughout the metabolic network [70]. Context-
specific FBA models can be developed to obtain flux predictions specific to individual cell 
lines or tumors, and custom objective functions can be used to analyze specific aspects of 
cellular metabolism of interest [71].
An FBA-based metabolic modeling pipeline that incorporates transcriptomic, kinetic, 
thermodynamic, and metabolite concentration data has previously been developed to make 
accurate predictions of NADPH production in radiation-sensitive (SCC-61) and radiation-
resistant (rSCC-61) head and neck squamous cell carcinoma (HNSCC) cell lines [72]. The 
goal of this model development was to compare intrinsic metabolic differences between the 
matched HNSCC cell lines that may yield phenotypic differences in sensitivity to NQO1-
dependent drugs such as β-lapachone. Using this modeling platform and an objective 
function of maximizing the reduction of NADP+ to NADPH, NADPH-production genes 
were discovered where knockdown causes distinct effects on total cellular NADPH 
production between SCC-61 and rSCC-61 cells. In addition, model predictions of NADPH 
production after simulated knockdown of 229 individual oxidoreductase genes matched well 
with experimental measurements of cell viability after 24 hours of β-lapachone exposure in 
siRNA-treated cell lines.
Modeling NADH metabolism in radiation-sensitive and -resistant HNSCC cell lines
FBA predictions of the most important genes and metabolic pathways towards NADH 
production are expected to yield valid targets for enhancing sensitivity to both radiation 
therapy and β-lapachone treatment. To this end, using an objective function of maximizing 
NADH production, parsimonious flux balance analysis (pFBA) was used to obtain a single 
representative flux vector in both SCC-61 and rSCC-61 cell lines that maximizes both the 
production of NAD+, as well as reduction of NAD+ to NADH.
The rSCC-61 model showed greater total NADH production than the SCC-61 model, with 
rSCC-61/SCC-61 = 1.24 (Figure 3). Both models displayed significant fluxes through the 
NAD+ salvage, purine salvage, and pentose phosphate pathways. The pentose phosphate 
pathway produces ribose 5-phosphate (R5P), which is converted into adenosine 
monophosphate (AMP) and phosphoribosyl pyrophosphate (PRPP) by 
phosphoribosylpyrophosphate synthase (PRPS). PRPP is converted to NMN and NAD+ by 
NAMPT and NMNAT, respectively, in the NAD+ salvage pathway, supplying both cell lines 
with sufficient amounts of NAD+. AMP is converted to other purines and members of the 
purine salvage pathway, eventually being excreted as uric acid. Through this pathway, NAD+ 
produced from the NAD+ salvage pathway can be reduced to NADH by both IMP 
dehydrogenase and xanthine oxidase. Additionally, ribose 1-phosphate (R1P) produced from 
xanthosine can be re-converted into R5P, entering back into the cycle. Thus, the 
interconnection of the pentose phosphate pathway, NAD+ salvage pathway, and purine 
salvage pathway plays an important role in both NAD+ synthesis and reduction to NADH in 
both cell lines.
To find selective targets of NAD+ and NADH production in radiation-resistant tumors, the 
metabolic reactions that had significantly greater flux in the radiation-resistant rSCC-61 cell 
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line compared to the radiation-sensitive SCC-61 cell line were determined, such that the 
rSCC-61/SCC-61 flux ratio was larger than the ratio of total NADH production (rSCC-61/
SCC-61 = 1.24). Both phosphopentomutase (PPM) and phosphoribosylpyrophosphate 
synthase (PRPS) had flux ratios of 1.36, and NAMPT had a flux ratio of 1.31. Previous 
studies have shown that inhibition of NAMPT decreases NAD+/NADH levels, increases 
levels of ROS, and sensitizes cancer cells to β-lapachone treatment [65, 66]. These 
computational and experimental findings suggest that combining NAMPT inhibitors with β-
lapachone and/or ionizing radiation may be an effective treatment strategy for radiation-
resistant tumors. Additionally, prior modeling and experimental findings showed that 
knockdown of NADPH-producing genes in the pentose phosphate pathway (including 
G6PD) causes greater sensitization towards β-lapachone in rSCC-61 cells than SCC-61 cells 
[72]. This corroborates with model predictions that reactions producing and consuming R5P 
may be valid targets for selectively suppressing NAD+ metabolism in radiation-resistant 
tumors.
Precision medicine approach towards targeting NAD+ metabolism
With the wealth of biological and clinical data becoming available, the precision medicine 
approach towards tailoring cancer therapies for individual patients is becoming more viable. 
This type of approach can help determine which therapies will best target NAD+ metabolism 
to increase radiation sensitivity in individual cancer patients. For example, PARP inhibitors 
are being selectively chosen for patients with homologous recombination (HR) deficiencies, 
including those with BRCA1/2 mutations [73, 74]. When cells are deficient in HR, they 
upregulate PARP1 alternative end-joining to compensate, making these tumors more 
sensitive to PARP inhibitors [75]. Additionally, by hindering PARP1’s auto-poly ADP-
ribosylation activity, PARP inhibitors prevent PARP1’s release from DNA, limiting access of 
DNA repair proteins to SSBs. If these SSBs remain, collision of unrepaired SSBs with the 
replication fork in S-phase of the cell cycle results in the generation of double-stranded 
breaks (DSBs) [22]. In patients with BRCA1/2 mutations, the DSB repair pathways are 
impaired, and the combination of both SSBs and DSBs results in greater tumor cell death 
and radiation sensitization. Because NQO1 activity is the principal determinant of β-
lapachone sensitivity, β-lapachone is being selectively chosen for patients with high 
expression levels of NQO1 [45].
Personalized genome-scale metabolic models of HNSCC patient tumors developed using 
transcriptomic data from The Cancer Genome Atlas (TCGA) have recapitulated many of the 
differences in NADPH metabolism between radiation-sensitive and -resistant HNSCC cell 
lines [72]. These types of models can be used to discover viable therapeutic targets in 
individual patients, including enzymes and metabolic reactions where intervention would 
best disrupt the NAD+ metabolic network and increase radiation sensitivity. Additionally, 
agent-based modeling will ultimately help establish the important role that cellular 
metabolic heterogeneity plays in the collective cellular behaviors seen in tumor growth and 
migration, as well as the tumor response to chemotherapy and radiation treatment [76]. 
Combining computational modeling with state-of-the-art experimental approaches including 
novel biosensors and patient-derived organoids will undoubtedly improve our ability to 
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target NAD+ metabolism to enhance radiation therapy responses in individual cancer 
patients.
Conclusion
By disrupting fundamental metabolic and signaling processes necessary for cancer cell 
survival, current NAD+-targeting therapies are showing tremendous promise in their ability 
to selectively enhance tumor sensitivity to radiation therapy. These therapies take advantage 
of our current understanding of the major influxes and effluxes from the cellular supply of 
NAD+, along with how these fluxes are disrupted in cancer and especially with the radiation-
resistant phenotype. Novel experimental techniques for sensing and modulating NAD+/
NADH, as well as computational systems biology methods of modeling NAD+ metabolism, 
will undoubtedly provide us with greater insights into these fundamental biological 
processes as well as novel targets for improving radiation response. As the availability and 
quality of multi-omic data derived from patient tumors increases, our ability to pinpoint 
specific disruptions in the NAD+ metabolic network and determine which therapies will best 
address these disruptions within individual patients will greatly improve. NAD+ metabolism 
remains a key aspect of oxidative metabolism as well as a promising target for enhancing 
radiation therapy responses.
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Figure 1. 
(A) Major biochemical pathways for the production of NAD+. (B) Major inputs and outputs 
to/from the cellular pools of NAD+, NADH, NADP+, and NADPH, including pathways and 
therapies pertinent to the cellular response to radiation therapy. Abbreviations: GLUD, 
glutamate dehydrogenase; ME2, malic enzyme 2; NA, nicotinic acid; MTHFD2L, 
methylenetetrahydrofolate dehydrogenase 2-like protein; NAAD, nicotinic acid 
dinucleotide; NADK, NAD+ kinase; NADS, NAD+ synthase; NAM, nicotinamide; NAMN, 
nicotinic acid mononucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NAPT, 
nicotinic acid phosphoribosyltransferase; NMN, nicotinamide mononucleotide; NMNAT, 
nicotinamide mononucleotide adenylyltransferase; NQO1, NAD(P)H:quinone 
oxidoreductase 1; NR, nicotinamide riboside; Nrf2, nuclear factor (erythroid-derived 2)-like 
2; NRK, nicotinamide riboside kinase; PARP, poly(ADP-ribose) polymerase; PDC, pyruvate 
dehydrogenase complex; QA, quinolinic acid; QPRT, quinolinate phosphoribosyltransferase; 
TCA, tricarboxylic acid cycle; Trp, tryptophan.
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Figure 2. 
Cooperative antitumor efficacy using a combination of β-lap and IR to treat HNC xenograft 
models. Mice bearing 30 mm3 SqCC/Y1 HNC xenografts with high levels of NQO1 
expression were treated with 2 Gy every other day for five treatments (10 Gy total dose). β-
lap-HPβ-CD 10 mg/kg was intravenously administered by tail-vein injection immediately 
following 2 Gy treatment. Vehicle alone (HPβ-CD) served as a control cohort (Materials and 
Methods). Results (means ± SE) are representative of repeated similar experiments (n=10 
for each group). Student’s t-tests (*** p < 0.001) were performed comparing treated vs 
control groups. (A) Tumor volume measurements and (B) Kaplan-Meier overall survival 
over the indicated number of days is graphed for control (HPβ-CD), β-lap-HPβ-CD 10 
mg/kg alone, 2 Gy alone and a combination of 2 Gy plus β-lap-HPβ-CD 10 mg/kg. Log-
rank analyses were performed comparing survival curves using various IR + β-lap-HPβ-CD 
regimens (*** p < 0.001 for the combined treatment compared to each single treatment). 
Survival curves show equivalency between HPβ-CD and β-lap-HPβ-CD 10 mg/kg. 
Reprinted from [49].
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Figure 3. Parsimonious flux balance analysis results in SCC-61 and rSCC-61 cell lines.
Cytosolic NADH production was maximized to determine the most pertinent metabolic 
pathways and reactions towards both NAD+ production and reduction of NAD+ to NADH. 
Red numbers indicate the ratio of predicted flux values for each reaction between rSCC-61/
SCC-61 cell lines. Abbreviations: AMP, adenosine monophosphate; AMPD, adenosine 
monophosphate deaminase; IMP, inosine monophosphate; IMPDH, inosine monophosphate 
dehydrogenase; NAM, nicotinamide; NAMPT, nicotinamide phosphoribosyltransferase; 
NMN, nicotinamide mononucleotide; NMNAT, nicotinamide mononucleotide 
adenylyltransferase; NT5, 5’-nucleotidase; PNP, purine-nucleoside phosphorylase; PPM, 
phosphopentomutase; PRPP, phosphoribosyl pyrophosphate; PRPS, phosphoribosyl 
pyrophosphate synthase; R1P, ribose 1-phosphate; R5P, ribose 5-phosphate; XDH, xanthine 
dehydrogenase/xanthine oxidase; XMP, xanthosine monophosphate.
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Table 1.
Methods for measuring NAD(H) redox state in various experimental settings.
In vitro Measurement Fluorescence Ratiometric Limitations
Autofluorescence [36] NADH Absorbance 340 nm; emission 
460 nm
- Weak signal, overlap with NADPH spectra, 
difficulties separating mitochondrial and 
cytosolic signals
NAD(H) redox sensors
Frex [37] NADH Excitation 420 nm and 500 nm, 
emission 518 nm
Yes pH-sensitive
Peredox [38] NAD+/NADH Excitation 400 nm, emission 510 
nm
No High affinity for the NADH can lead to 
saturation
rexYFP [39] NAD+/NADH Excitation 419 nm, emission 516 
nm
No pH-sensitive
SoNar [40] NAD+ and NADH Excitation 420 nm and 485 nm, 
emission 518 nm
Yes Fluorescence excited at 485 nm is pH-
sensitive
NAD+ sensor [41] NAD+ Excitation 405 nm and 500, 
emission 520 nm
Yes Slightly temperature sensitive
In tissue or cell lysates Measurement Limitations In vivo Measurement Limitations
Enzymatic cycling assays NAD+ and NADH Sensitivity NMR
HPLC [29] NAD+ Capacity for 
complex samples
31P [42] NAD+ and NADH Spectral overlap
LC-MS [30] NAD+ and NADH Optimization for 
complex samples
1P [43] NAD+ Partial NAD+ invisibility
SoNar [35] NAD+ and NADH SoNar’s coding DNA needs to be 
integrated into the genome
Semin Radiat Oncol. Author manuscript; available in PMC 2020 January 01.
